Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — Maxim Growth Conference Oct. 22-23, 2025
20 slides from Aim Immunotech's conference presentation, Oct 20, 2025
Slide 1: AIM ImmunoTech – Maxim Growth, Oct. 22-23, 2025
NYSE American: AIM aimimmuno.com AIM ImmunoTech Maxim Growth Oct. 22-23, 2025
Slide 2: Forward-looking statements
‘Some of the statements included in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Ref
Slide 3: Rich Pipeline with Pancreatic Cancer as Lead Indication
Rich Pipeline with Pancreatic Cancer as Lead Indication Late-stage clinical immuno-pharma company focused on developing therapeutics across a number of disease areas Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in human clinical studies with significant
Slide 4: Lead Program Ampligen® (rintatolimod)
Lead Program Ampligen® (rintatolimod)
Slide 5: Ampligen safety profile and approvals
Administered by intravenous (IV) infusion over 30 to 60 minutes Generally well-tolerated with >100,000 IV doses administered, also with successful Phase 1 intraperitoneal and intranasal safety clinical trials Extensive exposure to drug (>600 patient treatment years), including two placebo-controlled
Slide 6: Our AIM: Pancreatic Cancer Path to Phase 3 Pivotal Study
Our AIM Pancreatic Cancer: Preparing Clinical and Regulatory Path to Phase 3 Pivotal Study= Qaim
Slide 7: Ampligen: Mechanism of Action in Oncology
Ampligen: Mechanism of Action in Oncology Reprogramming of the Tumor Microenvironment to Convert ‘Cold’ Tumors Into ‘Hot’ Tumors that will be Responsive to Checkpoint Blockage Goal is to unleash the cellular immune response to attack and destroy cancer cells and increase survival* Ampligen’ is the o
Slide 8: Ensuring Effective Chemokine Modulation in Tumors is Important for Teff Cell Infiltration
Ensuring Effective Chemokine Modulation in Tumors is Important for Teff Cell Infiltration and Increased Survival Ampligen (dsRNA/TLR3 agonist)-containing cocktails have shown an ability in vivo to increase CXCL10 and decrease CCL22 intratumorally with associated increase in 5 the Teff/Treg ratio in
Slide 9: Late-Stage Metastatic and Locally-Advanced Pancreatic Cancer Focus
Late-Stage Metastatic and Locally-Advanced Pancreatic Cancer Are the Focus of Ampligen’s Development Track Pancreatic Cancer Snapshot 1 Pancreatic cancer is a highly unmet need that is expected to be the 2nd- leading cause of cancer deaths by 20307 1. Word Cancer +h Fund 2. Pancreatic Cancer Action
Slide 10: Intellectual Property Portfolio
Intellectual Property Portfolio Laying the groundwork for success in pancreatic cancer Patent protection regarding pancreatic cancer and oncology development * United States - Methods involve the administration of a unique synergistic combination of Ampligen and an anti-PD-L1 in the treatment of pan
Slide 11: Foundation of Success in Pancreatic Cancer
Foundation of Success in Pancreatic Cancer Early Access Program (EAP) Indicated Statistically Significant Increased Overall Survival Compared to Historical Controls in the Treatment of Late-Stage Pancreatic Cancer Erasmus University Medical Center. sohort comp fit compared to \S jient-reported measu
Slide 12: DURIPANC Phase Metastatic Pancreatic Cancer Clinical Trial
DURIPANC Phase 2 Metastatic Pancreatic Cancer Clinical Trial A steppingstone to a pivotal Phase 3 trial * Sponsor: Erasmus University Medical Center Collaborators: AIM ImmunoTech and AstraZeneca Study Title: Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod
Slide 13: DURIPANC Mid-Year Results
DURIPANC Mid-Year Results am Safety * Toxicity - No grade 22 immune-related or systemic toxicities reported to date Efficacy * Progression-Free Survival (PFS) - Among the 14 patients evaluable for progression-free survival, eight patients experienced disease progression within 6 months of treatment
Slide 14: Oncology has seen major Big Pharma Deals in 2025
Oncology has seen major Big Pharma Deals in 2025 AIM believes that continued success in pancreatic cancer could lead to financial success for our stockholders Qaim
Slide 15: Positive Data from Secondary Target Oncology Indications
Positive Data from Secondary Target Oncology Indications Represent Significant Unmet Needs \ppo uni 19,880 287,850 | 151,030 99,780 New Cases Annually? New Cases Annually? New Cases Annually? New Cases Annually? 12,810 43,250 52,580 7,650 Deaths Annually? Deaths Annually? Deaths Annually? Deaths Ann
Slide 16: Advanced, Recurrent Ovarian Cancer
Advanced, Recurrent Ovarian Cancer 16 Qaim Phase 2 Advanced, Recurrent Ovarian Cancer AMPLIGEN / KEYTRUDA Combo Status Positive results expected in Q4 2025, Study Drug ‘Ampligen and KEYTRUDA Primary Endpoint Objective Response Rate (ORR) Study Collaborators MERCK Ge Bite Clinical Trials NCT # NCTO37
Slide 17: Our AIM: Corporate Overview
Slide 18: Proven Management Team
Proven Management Team C6 2 | BIOFLORIDA [= Fast GreenbergTraurig Peter W. Rodino Ill, JD Rodino Consulting; Chief Operating Officer, Executive Director for Governmental Rodino & Rodino; , Rodino & Scalera Inc.; Relations, General Counsel, Secretary Foundation Health FORESITE ADVISORS @) harp VYOME
Slide 19: Intellectual Property Portfolio — Market Exclusivity
Intellectual Property Portfolio — Market Exclusivity Orphan D gnation (FDA and EMA) 55 39 Patents Pending Worldwide Applications
Slide 20: Focused On Clinical Execution
Focused On Clinical Execution Unlocking the value of Ampligen with the goal of new drug approval in pancreatic cancer > ab,
AIM ImmunoTech — Maxim Growth Conference Oct. 22-23, 2025 on 6ix